Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.
Neuraxpharm is aiming to expand in the Portuguese market with its first commercial launch lined up for December. Javier Mercadé will be heading up the southern European region comprising Italy, Spain and now Portugal.
With Endo’s CEO Paul Campanelli intending to step down for personal reasons, the US brands and generics player’s board has started to look for external and internal candidates to take over.
Biocon has appointed a new CEO, while Mundipharma and Acino have named regional managers. At the same time, Nelipak has also appointed a new CEO.
Teva has announced a leadership change in its global operations, while Lupin has made a key appointment to focus on quality and compliance. Among other changes in leadership roles, Olainfarm has seen one of its six management board members resign.
Alvotech has brought in a Pfizer biosimilars specialist as chief scientific officer, while Lupin has recruited a women’s health expert to head its US Specialty business. And Ian Read is to retire as Pfizer’s chairman at the start of next year.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.